Biotech Values

[akasidney86]

Brillant defensive counter-attack, as IMO it either a) halts any decision from the FDA for the duration of the suit, b) provides grounds for injunctive sales relief in the event of an FDA approval, or c) shows that Teva doesn't have the horses in the first place and it's dismissed. In any event it's years of m-enox sales guaranteed.

My question would be in the event of b), would MNTA go to a royalty position even though there is in fact no third product actually on the market due to pending legal action?